The efficacy and safety of ixekizumab, adalimumab, and placebo in patients with psoriatic arthritis naive to biological disease-modifying anti-rheumatic drugs: a double-blind phase 3 study
Author(s):
Mease, P.; Heijde, D. van der; Ritchlin, C.; Cuchacovich, R.; Shuler, C.; Lin, C.Y.; Vangerow, H.; Samanta, S.; Lee, C.H.; Gladman, D.; Larsson, E.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-12-31
Language
English
Is part of
Scandinavian Journal of Rheumatology (2016), Vol. 45, p. 31-33
